Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Oncolytics Biotech Inc. (NASDAQ:ONCY) is a Canadian development-stage biopharmaceutical company founded in 1998 and headquartered in Calgary, Alberta. The company went public in 2001 and has spent over two decades developing its lead therapeutic candidate, pelareorep, an oncolytic virus-based immunotherapy for cancer treatment. As a clinical-stage biotechnology company, Oncolytics has no commercial products and generates no revenue, instead focusing entirely on advancing pelareorep through various clinical trials targeting multiple cancer types including breast, pancreatic, and anal cancers.
Latest newsMore news →
Oncolytics Biotech announced positive preclinical results for pelareorep combined with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.10d agoOncolytics Biotech Inc. appointed Stephen Glover as a director, with an option to purchase 96,000 shares vesting over three years.111d agoOncolytics Biotech Inc. appointed John McAdory as Chief Operating Officer, effective June 1, 2026.111d ago